YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
GSK (LSE:GSK) has entered a collaboration with Wave Life Sciences to advance a GalNAc-siRNA hepatology candidate into its development pipeline. The partnership with Wave Life Sciences focuses on RNA-based therapies targeting liver diseases…
RNA therapeutics are medicines that use RNA molecules to influence gene expression or protein production. Unlike many conventional drugs that act directly on proteins, RNA medicines can intervene earlier in the process by reducing disease-…
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast…
Shares of Sarepta Therapeutics SRPT fell nearly 10% over the past week. This decline likely reflects growing investor concerns about the company's position in the Duchenne muscular dystrophy (DMD) landscape following a key regulatory miles…
An updated edition of the June 2, 2026, article. Genomics is a broad and detailed study of genomes (an organism's complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this area have heightened interest from pharmace…
uniQure N.V. QURE has surged as investors reassessed AMT-130, its lead gene therapy candidate for Huntington's disease. The question is whether the move already reflects too much optimism. Valuation, earnings quality, estimate trends and r…
uniQure N.V. QURE remains a catalyst-driven gene therapy stock, with AMT-130 shaping most of the investment debate. The program targets Huntington's disease, an area where disease-modifying options remain absent. Recent FDA feedback, a tar…
(RTTNews) - Wave Life Sciences Ltd. (WVE) has begun the Phase 2a portion of its INLIGHT trial, evaluating WVE-007, an investigational GalNAc-siRNA therapy, in individuals living with obesity and related metabolic conditions. The study is a…
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing Phase 2a portion in individuals with higher…
Is SNY a good stock to buy? We came across a bullish thesis on Sanofi on r/ValueInvesting by stefanliemawan. In this article, we will summarize the bulls' thesis on SNY. Sanofi's share was trading at $42.38 as of June 18th. SNY's trailing…
Is WVE a good stock to buy? We came across a bullish thesis on Wave Life Sciences Ltd. on Biotech Distilled's Substack. In this article, we will summarize the bulls' thesis on WVE. Wave Life Sciences Ltd.'s share was trading at $5.70 as of…
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that mem…
Key Points Exome sold 421,488 shares of Wave Life Sciences; the estimated trade size was $5.49 million based on quarterly average prices. The quarter-end value of the position decreased by $7.17 million as a result. This transaction repres…
On May 15, 2026, Exome Asset Management reported selling out of Wave Life Sciences(NASDAQ:WVE), liquidating 421,488 shares in an estimated $5.49 million trade based on quarterly average pricing. What happened According to an SEC filing dat…
Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing On track for feedback from…
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul…
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s obesity and metabolic illness initiatives, TD Cowen reiterated its…
Wave Life Sciences (WVE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items. T…
Major earnings expected before the bell on Tuesday include: * The Coca-Cola Company (KO [https://seekingalpha.com/symbol/KO]) * Enterprise Products Partners L.P. (EPD [https://seekingalpha.com/symbol/EPD]) * General Motors Company (GM [htt…
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The company’s stock registered a 22.39% growth from a year ago and a 53.04% percent decline year-to-date. Based on analyst consen…
In this article, we will look at the 5 Best Small-Cap Biotech Stocks According to Hedge Funds. Please visit 10 Best Small-Cap Biotech Stocks According to Hedge Funds if you’d like to see an extended list and methodology behind it. 5. Nuvat…
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the 8 Healthcare Stocks Insiders Are Buying. On April 7, 2026, RBC Capital analyst Luca Issi lowered the price target on Wave Life Sciences Ltd. (NASDAQ:WVE) to $15 from $27 and maintained an…
Shares of Wave Life Sciences(NASDAQ: WVE) recently fell off a cliff after the small-cap biotech reported results from a phase 1 clinical trial of its investigational weight-loss drug, WVE-007. The data did not look great and are unlikely t…
Key Points Wave Life Sciences' shares dropped after its weight loss candidate failed to impress in a phase 1 study. However, this product could actually be successful if it can confirm its recent phase 1 results. 10 stocks we like better t…
We recently compiled a list of the 13 Best Stocks to Invest In on Robinhood for Beginners. Wave Life Sciences Ltd. is among the best Robinhood stocks to invest in. TheFly reported earlier on March 10 that Canaccord Genuity raised its price…
Wave Life Sciences (WVE) shares crashed more than 50% on Mardh 26 after the company’s interim Phase 1 data for its obesity candidate WVE-007 disappointed investors. This immense pressure on Thursday saw WVE’s relative strength index (14-da…
Shares of Wave Life Sciences WVE plunged 49.6% yesterday after the company announced new data from the phase I portion of the INLIGHT study evaluating its investigational pipeline candidate, WVE-007, in otherwise healthy individuals who ar…
Wave Life Sciences(NASDAQ:WVE), developer of RNA medicines for rare genetic diseases, closed Thursday at $6.20, down 49.59% for the session. The stock sank after disappointing higher-dose WVE-007 obesity data underperformed the lower dose.…
Wave Life Sciences(NASDAQ:WVE), developer of RNA medicines for rare genetic diseases, closed Thursday at $6.20, down 49.59% for the session. The stock sank after disappointing higher-dose WVE-007 obesity data underperformed the lower dose.…
US stocks sank on Thursday, with Big Tech and semiconductor stocks leading the sell-off. Conflicting messages from the US and Iran fueled mounting uncertainty over the Middle East conflict as oil hovered above $100. The tech-heavy Nasdaq C…
US stocks accelerated losses on Thursday, with Big Tech and semiconductor stocks leading the market sell-off. Conflicting messages from the US and Iran fueled mounting uncertainty over the Middle East conflict as oil hovered above $100. Th…
US stocks accelerated losses on Thursday, with Big Tech and semiconductor stocks leading the market sell-off. Conflicting messages from the US and Iran fueled mounting uncertainty over the Middle East conflict as oil hovered above $100. Th…
US stocks accelerated losses on Thursday as conflicting messages from the US and Iran fueled mounting uncertainty about the prospects for talks to end the Middle East conflict. The S&P 500 (^GSPC) fell 1.5%, while the tech-heavy Nasdaq Com…
All three major US stock indexes were down in late-morning trading on Thursday as investors attempt PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
(Bloomberg) -- Wave Life Sciences Ltd. shares plunged their most on record after a single, higher-dose shot of its weight-loss drug failed to meet investor expectations for reducing visceral fat. The medicine, known as WVE-007, is intended…
US stocks pulled back on Thursday as conflicting messages from the US and Iran fueled mounting uncertainty about the prospects for talks to end the Middle East conflict. The S&P 500 (^GSPC) fell 1%, while the tech-heavy Nasdaq Composite (^…